MSC V MPC, page-14

"Amused" (cool trading name by the way).

I am just not sure anyone actually needs to work with CYP. There are a bunch of other ways to achieve the same outcome. Their IP is really limited and almost unforceable. I am not saying they are a "quack" company (not at all) but I am just not sure there is an exit.

The market cap for CYP is not in line for a company at this level of development (ie non-clinical) and they are insufficiently capitalised for real clinical development. If you get "basic" and look at multiples (as a manufacturing technology company) they are trading at ~1,500 revenue, which is stupid.

Personally I am always wary of biotech companies that do reverse-mergers. Not all, but some. They often circumvent underwriter diligence for a reason. Not saying that this is the case here... But...